Novartis has received the US Food and Drug Administration (FDA) approval for the Kisqali Femara Co-Pack to treat hormone receptor-positive, human epidermal growth factor receptor-2 negative (HR+ / HER2-) advanced or metastatic breast cancer in postmenopausal women.

The company claimed that Kisqali Femara Co-Pack (ribociclib tablets; letrozole tablets) is the only available combination pack with two prescription products in advanced breast cancer.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Novartis oncology executive vice president and US head Bill Hinshaw said: “As we strive to keep the patient at the centre of every decision that we make at Novartis, we are pleased that collaborating closely with the FDA has resulted in our being able to offer this unique combination pack of two prescription cancer medicines.

“Providing physicians with a convenient one-package prescribing option for their patients underscores our commitment to deliver innovative treatment solutions to the metastatic breast cancer community.”

"Providing physicians with a convenient one-package prescribing option for their patients underscores our commitment to deliver innovative treatment solutions to the metastatic breast cancer community."

Kisqali (ribociclib) is a selective, cyclin-dependent kinase inhibitor that decelerates the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6).

It is developed by the Novartis Institutes for BioMedical Research (NIBR) under a research collaboration with Astex Pharmaceuticals.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Femara (letrozole) is a form of hormone therapy known as an aromatase inhibitor, which reduces the amount of oestrogen produced in the bodies of postmenopausal women.

The approval will allow the US physicians to prescribe Kisqali as the new Co-Pack or as two separate prescriptions and any aromatase inhibitor.

The Kisqali Femara Co-Pack will be made available in three dosage strengths by the end of this month in the US at both specialist and retail pharmacies.